Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis.
Identifieur interne : 002189 ( PubMed/Checkpoint ); précédent : 002188; suivant : 002190Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis.
Auteurs : Joel N H. Stern [États-Unis] ; Zsolt Illés ; Jayagopala Reddy ; Derin B. Keskin ; Masha Fridkis-Hareli ; Vijay K. Kuchroo ; Jack L. StromingerSource :
- Proceedings of the National Academy of Sciences of the United States of America [ 0027-8424 ] ; 2005.
Descripteurs français
- KwdFr :
- Animaux, Conception de médicament, Données de séquences moléculaires, Encéphalomyélite auto-immune expérimentale (immunologie), Encéphalomyélite auto-immune expérimentale (traitement médicamenteux), Lignée cellulaire, Lymphocytes T (), Lymphocytes T (immunologie), Peptides (), Peptides (pharmacologie), Peptides (synthèse chimique), Peptides (usage thérapeutique), Souris, Séquence d'acides aminés, Transfert adoptif.
- MESH :
- immunologie : Encéphalomyélite auto-immune expérimentale, Lymphocytes T.
- pharmacologie : Peptides.
- synthèse chimique : Peptides.
- traitement médicamenteux : Encéphalomyélite auto-immune expérimentale.
- usage thérapeutique : Peptides.
- Animaux, Conception de médicament, Données de séquences moléculaires, Lignée cellulaire, Lymphocytes T, Peptides, Souris, Séquence d'acides aminés, Transfert adoptif.
English descriptors
- KwdEn :
- Adoptive Transfer, Amino Acid Sequence, Animals, Cell Line, Drug Design, Encephalomyelitis, Autoimmune, Experimental (drug therapy), Encephalomyelitis, Autoimmune, Experimental (immunology), Mice, Molecular Sequence Data, Peptides (chemical synthesis), Peptides (chemistry), Peptides (pharmacology), Peptides (therapeutic use), T-Lymphocytes (drug effects), T-Lymphocytes (immunology).
- MESH :
- chemical , chemical synthesis : Peptides.
- chemical , chemistry : Peptides.
- drug effects : T-Lymphocytes.
- drug therapy : Encephalomyelitis, Autoimmune, Experimental.
- immunology : Encephalomyelitis, Autoimmune, Experimental, T-Lymphocytes.
- chemical , pharmacology : Peptides.
- chemical , therapeutic use : Peptides.
- Adoptive Transfer, Amino Acid Sequence, Animals, Cell Line, Drug Design, Mice, Molecular Sequence Data.
Abstract
Myelin basic protein (MBP) is a major candidate autoantigen in multiple sclerosis (MS). Its immunodominant epitope, MBP 85-99, forms a complex with human leukocyte antigen (HLA)-DR2 with which multiple sclerosis is genetically associated. Copolymer 1 (Copaxone), a random amino acid copolymer [poly (Y,E,A,K)n] as well as two modified synthetic copolymers [poly (F,Y,A,K)n and poly (V,W,A,K)n] also form complexes with HLA-DR2 (DRA/DRB1*1501) and compete with MBP 85-99 for binding. Moreover, two high-affinity synthetic peptide 15-mers that could inhibit binding even more effectively were previously designed. Here, we show that further-modified peptide 15-mers inhibited even more strongly (in order J5 > J3 > J2) both the binding of MBP 85-99 to HLA-DR2 and IL-2 production by two MBP 85-99-specific HLA-DR2-restricted T cells. J5, J3, and J2 also suppressed both MBP 85-99-induced experimental autoimmune encephalomyelitis (EAE) in humanized mice and proteolipid protein 139-151-induced EAE in SJL/J mice. Moreover, none of these previously uncharacterized peptide inhibitors crossreacted with MBP 85-99- or proteolipid protein 139-151-specific T cells. In both cases, spleen and lymph node cultures stimulated with these peptides produced large amounts of Th2 cytokines (IL-4 and IL-10), and adoptive transfer of established T cell lines suppressed disease induction. These peptide 15-mers provide specific, nonrandom sequences that appear to be at least as effective as random copolymers in suppressing EAE in several models.
DOI: 10.1073/pnas.0409022102
PubMed: 15665083
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:15665083Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis.</title><author><name sortKey="Stern, Joel N H" sort="Stern, Joel N H" uniqKey="Stern J" first="Joel N H" last="Stern">Joel N H. Stern</name><affiliation wicri:level="4"><nlm:affiliation>Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138</wicri:regionArea><placeName><region type="state">Massachusetts</region><settlement type="city">Cambridge (Massachusetts)</settlement></placeName><orgName type="university">Université Harvard</orgName></affiliation></author><author><name sortKey="Illes, Zsolt" sort="Illes, Zsolt" uniqKey="Illes Z" first="Zsolt" last="Illés">Zsolt Illés</name></author><author><name sortKey="Reddy, Jayagopala" sort="Reddy, Jayagopala" uniqKey="Reddy J" first="Jayagopala" last="Reddy">Jayagopala Reddy</name></author><author><name sortKey="Keskin, Derin B" sort="Keskin, Derin B" uniqKey="Keskin D" first="Derin B" last="Keskin">Derin B. Keskin</name></author><author><name sortKey="Fridkis Hareli, Masha" sort="Fridkis Hareli, Masha" uniqKey="Fridkis Hareli M" first="Masha" last="Fridkis-Hareli">Masha Fridkis-Hareli</name></author><author><name sortKey="Kuchroo, Vijay K" sort="Kuchroo, Vijay K" uniqKey="Kuchroo V" first="Vijay K" last="Kuchroo">Vijay K. Kuchroo</name></author><author><name sortKey="Strominger, Jack L" sort="Strominger, Jack L" uniqKey="Strominger J" first="Jack L" last="Strominger">Jack L. Strominger</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15665083</idno><idno type="pmid">15665083</idno><idno type="doi">10.1073/pnas.0409022102</idno><idno type="wicri:Area/PubMed/Corpus">002351</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002351</idno><idno type="wicri:Area/PubMed/Curation">002351</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002351</idno><idno type="wicri:Area/PubMed/Checkpoint">002189</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002189</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis.</title><author><name sortKey="Stern, Joel N H" sort="Stern, Joel N H" uniqKey="Stern J" first="Joel N H" last="Stern">Joel N H. Stern</name><affiliation wicri:level="4"><nlm:affiliation>Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138</wicri:regionArea><placeName><region type="state">Massachusetts</region><settlement type="city">Cambridge (Massachusetts)</settlement></placeName><orgName type="university">Université Harvard</orgName></affiliation></author><author><name sortKey="Illes, Zsolt" sort="Illes, Zsolt" uniqKey="Illes Z" first="Zsolt" last="Illés">Zsolt Illés</name></author><author><name sortKey="Reddy, Jayagopala" sort="Reddy, Jayagopala" uniqKey="Reddy J" first="Jayagopala" last="Reddy">Jayagopala Reddy</name></author><author><name sortKey="Keskin, Derin B" sort="Keskin, Derin B" uniqKey="Keskin D" first="Derin B" last="Keskin">Derin B. Keskin</name></author><author><name sortKey="Fridkis Hareli, Masha" sort="Fridkis Hareli, Masha" uniqKey="Fridkis Hareli M" first="Masha" last="Fridkis-Hareli">Masha Fridkis-Hareli</name></author><author><name sortKey="Kuchroo, Vijay K" sort="Kuchroo, Vijay K" uniqKey="Kuchroo V" first="Vijay K" last="Kuchroo">Vijay K. Kuchroo</name></author><author><name sortKey="Strominger, Jack L" sort="Strominger, Jack L" uniqKey="Strominger J" first="Jack L" last="Strominger">Jack L. Strominger</name></author></analytic><series><title level="j">Proceedings of the National Academy of Sciences of the United States of America</title><idno type="ISSN">0027-8424</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adoptive Transfer</term><term>Amino Acid Sequence</term><term>Animals</term><term>Cell Line</term><term>Drug Design</term><term>Encephalomyelitis, Autoimmune, Experimental (drug therapy)</term><term>Encephalomyelitis, Autoimmune, Experimental (immunology)</term><term>Mice</term><term>Molecular Sequence Data</term><term>Peptides (chemical synthesis)</term><term>Peptides (chemistry)</term><term>Peptides (pharmacology)</term><term>Peptides (therapeutic use)</term><term>T-Lymphocytes (drug effects)</term><term>T-Lymphocytes (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Conception de médicament</term><term>Données de séquences moléculaires</term><term>Encéphalomyélite auto-immune expérimentale (immunologie)</term><term>Encéphalomyélite auto-immune expérimentale (traitement médicamenteux)</term><term>Lignée cellulaire</term><term>Lymphocytes T ()</term><term>Lymphocytes T (immunologie)</term><term>Peptides ()</term><term>Peptides (pharmacologie)</term><term>Peptides (synthèse chimique)</term><term>Peptides (usage thérapeutique)</term><term>Souris</term><term>Séquence d'acides aminés</term><term>Transfert adoptif</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Peptides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Peptides</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>T-Lymphocytes</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Encephalomyelitis, Autoimmune, Experimental</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Encéphalomyélite auto-immune expérimentale</term><term>Lymphocytes T</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Encephalomyelitis, Autoimmune, Experimental</term><term>T-Lymphocytes</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Peptides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Peptides</term></keywords><keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>Peptides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Peptides</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Encéphalomyélite auto-immune expérimentale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Peptides</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adoptive Transfer</term><term>Amino Acid Sequence</term><term>Animals</term><term>Cell Line</term><term>Drug Design</term><term>Mice</term><term>Molecular Sequence Data</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Conception de médicament</term><term>Données de séquences moléculaires</term><term>Lignée cellulaire</term><term>Lymphocytes T</term><term>Peptides</term><term>Souris</term><term>Séquence d'acides aminés</term><term>Transfert adoptif</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Myelin basic protein (MBP) is a major candidate autoantigen in multiple sclerosis (MS). Its immunodominant epitope, MBP 85-99, forms a complex with human leukocyte antigen (HLA)-DR2 with which multiple sclerosis is genetically associated. Copolymer 1 (Copaxone), a random amino acid copolymer [poly (Y,E,A,K)n] as well as two modified synthetic copolymers [poly (F,Y,A,K)n and poly (V,W,A,K)n] also form complexes with HLA-DR2 (DRA/DRB1*1501) and compete with MBP 85-99 for binding. Moreover, two high-affinity synthetic peptide 15-mers that could inhibit binding even more effectively were previously designed. Here, we show that further-modified peptide 15-mers inhibited even more strongly (in order J5 > J3 > J2) both the binding of MBP 85-99 to HLA-DR2 and IL-2 production by two MBP 85-99-specific HLA-DR2-restricted T cells. J5, J3, and J2 also suppressed both MBP 85-99-induced experimental autoimmune encephalomyelitis (EAE) in humanized mice and proteolipid protein 139-151-induced EAE in SJL/J mice. Moreover, none of these previously uncharacterized peptide inhibitors crossreacted with MBP 85-99- or proteolipid protein 139-151-specific T cells. In both cases, spleen and lymph node cultures stimulated with these peptides produced large amounts of Th2 cytokines (IL-4 and IL-10), and adoptive transfer of established T cell lines suppressed disease induction. These peptide 15-mers provide specific, nonrandom sequences that appear to be at least as effective as random copolymers in suppressing EAE in several models.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15665083</PMID><DateCompleted><Year>2005</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN><JournalIssue CitedMedium="Print"><Volume>102</Volume><Issue>5</Issue><PubDate><Year>2005</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation></Journal><ArticleTitle>Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis.</ArticleTitle><Pagination><MedlinePgn>1620-5</MedlinePgn></Pagination><Abstract><AbstractText>Myelin basic protein (MBP) is a major candidate autoantigen in multiple sclerosis (MS). Its immunodominant epitope, MBP 85-99, forms a complex with human leukocyte antigen (HLA)-DR2 with which multiple sclerosis is genetically associated. Copolymer 1 (Copaxone), a random amino acid copolymer [poly (Y,E,A,K)n] as well as two modified synthetic copolymers [poly (F,Y,A,K)n and poly (V,W,A,K)n] also form complexes with HLA-DR2 (DRA/DRB1*1501) and compete with MBP 85-99 for binding. Moreover, two high-affinity synthetic peptide 15-mers that could inhibit binding even more effectively were previously designed. Here, we show that further-modified peptide 15-mers inhibited even more strongly (in order J5 > J3 > J2) both the binding of MBP 85-99 to HLA-DR2 and IL-2 production by two MBP 85-99-specific HLA-DR2-restricted T cells. J5, J3, and J2 also suppressed both MBP 85-99-induced experimental autoimmune encephalomyelitis (EAE) in humanized mice and proteolipid protein 139-151-induced EAE in SJL/J mice. Moreover, none of these previously uncharacterized peptide inhibitors crossreacted with MBP 85-99- or proteolipid protein 139-151-specific T cells. In both cases, spleen and lymph node cultures stimulated with these peptides produced large amounts of Th2 cytokines (IL-4 and IL-10), and adoptive transfer of established T cell lines suppressed disease induction. These peptide 15-mers provide specific, nonrandom sequences that appear to be at least as effective as random copolymers in suppressing EAE in several models.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Joel N H</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Illés</LastName><ForeName>Zsolt</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Reddy</LastName><ForeName>Jayagopala</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Keskin</LastName><ForeName>Derin B</ForeName><Initials>DB</Initials></Author><Author ValidYN="Y"><LastName>Fridkis-Hareli</LastName><ForeName>Masha</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kuchroo</LastName><ForeName>Vijay K</ForeName><Initials>VK</Initials></Author><Author ValidYN="Y"><LastName>Strominger</LastName><ForeName>Jack L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS030843</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI 49524</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI049524</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS30843</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS38037</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS038037</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>01</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019264" MajorTopicYN="N">Adoptive Transfer</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004681" MajorTopicYN="N">Encephalomyelitis, Autoimmune, Experimental</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>1</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>3</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>1</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15665083</ArticleId><ArticleId IdType="pii">0409022102</ArticleId><ArticleId IdType="doi">10.1073/pnas.0409022102</ArticleId><ArticleId IdType="pmc">PMC547868</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Immunity. 1995 Oct;3(4):397-405</Citation><ArticleIdList><ArticleId IdType="pubmed">7584131</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1995 Jul;45(7):1268-76</Citation><ArticleIdList><ArticleId IdType="pubmed">7617181</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 1996 Oct 31;795:216-26</Citation><ArticleIdList><ArticleId IdType="pubmed">8958933</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Immunol. 1997 Nov;27(11):3059-69</Citation><ArticleIdList><ArticleId IdType="pubmed">9394837</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1998 Mar;50(3):701-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9521260</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1998 May 1;160(9):4386-97</Citation><ArticleIdList><ArticleId IdType="pubmed">9574543</ArticleId></ArticleIdList></Reference><Reference><Citation>Braz J Med Biol Res. 1998 Jan;31(1):55-60</Citation><ArticleIdList><ArticleId IdType="pubmed">9686179</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1998 Oct 1;161(7):3299-306</Citation><ArticleIdList><ArticleId IdType="pubmed">9759845</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 1998 Oct 19;188(8):1511-20</Citation><ArticleIdList><ArticleId IdType="pubmed">9782128</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1999 Feb 1;162(3):1811-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9973446</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1999 Apr 15;162(8):4697-704</Citation><ArticleIdList><ArticleId IdType="pubmed">10202010</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1999 Nov;23(3):343-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10610182</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2000 Apr 11;54(7):1414-20</Citation><ArticleIdList><ArticleId IdType="pubmed">10751249</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 2000 Apr 17;191(8):1395-412</Citation><ArticleIdList><ArticleId IdType="pubmed">10770805</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2000 Oct;6(10):1167-75</Citation><ArticleIdList><ArticleId IdType="pubmed">11017150</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2000 Oct;6(10):1176-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11017151</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Immunol. 2001 Aug;62(8):753-63</Citation><ArticleIdList><ArticleId IdType="pubmed">11476898</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2001 Sep 1;167(5):2688-93</Citation><ArticleIdList><ArticleId IdType="pubmed">11509612</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2002 Jun;109(12):1635-43</Citation><ArticleIdList><ArticleId IdType="pubmed">12070311</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2003 Jan 15;170(2):870-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12517952</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autoimmun. 2003 Jun;20(4):265-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12791309</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11749-54</Citation><ArticleIdList><ArticleId IdType="pubmed">15292513</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11743-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15292514</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Oct 26;101(43):15434-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15492218</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Immunol. 1971 Aug;1(4):242-8</Citation><ArticleIdList><ArticleId IdType="pubmed">5157960</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Immunol. 1973 May;3(5):273-9</Citation><ArticleIdList><ArticleId IdType="pubmed">4128127</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Immunol Immunopathol. 1974 Nov;3(2):256-62</Citation><ArticleIdList><ArticleId IdType="pubmed">4141659</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiol Rev. 1982;4:45-65</Citation><ArticleIdList><ArticleId IdType="pubmed">6754409</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1987 Aug 13;317(7):408-14</Citation><ArticleIdList><ArticleId IdType="pubmed">3302705</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1989 Mar 1;142(5):1523-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2465343</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1990 Feb 9;247(4943):718-21</Citation><ArticleIdList><ArticleId IdType="pubmed">1689076</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Today. 1991 Aug;12(8):277-82</Citation><ArticleIdList><ArticleId IdType="pubmed">1716903</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathobiology. 1991;59(5):305-12</Citation><ArticleIdList><ArticleId IdType="pubmed">1716908</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1992 Nov 27;258(5087):1491-4</Citation><ArticleIdList><ArticleId IdType="pubmed">1279812</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Immunol. 1993 Jan;23(1):17-25</Citation><ArticleIdList><ArticleId IdType="pubmed">8419168</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1993 Nov 17;270(19):2362-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8230601</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 1994 Jan 1;179(1):279-90</Citation><ArticleIdList><ArticleId IdType="pubmed">7505801</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmunol. 1994 Feb;50(1):95-100</Citation><ArticleIdList><ArticleId IdType="pubmed">8300862</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 1994 Dec 1;180(6):2227-37</Citation><ArticleIdList><ArticleId IdType="pubmed">7525850</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10859-63</Citation><ArticleIdList><ArticleId IdType="pubmed">7526383</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Immunol. 1995 Jul;101 Suppl 1:9-12</Citation><ArticleIdList><ArticleId IdType="pubmed">7606862</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1995 Jul 15;155(2):982-92</Citation><ArticleIdList><ArticleId IdType="pubmed">7541828</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1996 Jan 25;379(6563):343-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8552189</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Massachusetts</li></region><settlement><li>Cambridge (Massachusetts)</li></settlement><orgName><li>Université Harvard</li></orgName></list><tree><noCountry><name sortKey="Fridkis Hareli, Masha" sort="Fridkis Hareli, Masha" uniqKey="Fridkis Hareli M" first="Masha" last="Fridkis-Hareli">Masha Fridkis-Hareli</name><name sortKey="Illes, Zsolt" sort="Illes, Zsolt" uniqKey="Illes Z" first="Zsolt" last="Illés">Zsolt Illés</name><name sortKey="Keskin, Derin B" sort="Keskin, Derin B" uniqKey="Keskin D" first="Derin B" last="Keskin">Derin B. Keskin</name><name sortKey="Kuchroo, Vijay K" sort="Kuchroo, Vijay K" uniqKey="Kuchroo V" first="Vijay K" last="Kuchroo">Vijay K. Kuchroo</name><name sortKey="Reddy, Jayagopala" sort="Reddy, Jayagopala" uniqKey="Reddy J" first="Jayagopala" last="Reddy">Jayagopala Reddy</name><name sortKey="Strominger, Jack L" sort="Strominger, Jack L" uniqKey="Strominger J" first="Jack L" last="Strominger">Jack L. Strominger</name></noCountry><country name="États-Unis"><region name="Massachusetts"><name sortKey="Stern, Joel N H" sort="Stern, Joel N H" uniqKey="Stern J" first="Joel N H" last="Stern">Joel N H. Stern</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002189 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002189 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:15665083
|texte= Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:15665083" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |